NanoVation Therapeutics Partners with Novo Nordisk to Develop Genetic Medicines for Cardiometabolic and Rare Diseases
Overview of the Deal:
NanoVation Therapeutics has entered into a multi-year partnership with Novo Nordisk to develop cutting-edge genetic medicines that target cardiometabolic and rare diseases. Announced on September 18, 2024, this collaboration will leverage NanoVation’s long-circulating lipid nanoparticle (lcLNP™) technology, which enables RNA delivery to cells outside the liver, combined with Novo Nordisk’s expertise in developing therapies for cardiometabolic and rare genetic diseases. This partnership marks a significant step forward in the development of next-generation genetic medicines.
NanoVation’s Technology and Collaboration Focus:
NanoVation’s lcLNP™ technology is at the heart of this collaboration, addressing the challenges of conventional nucleic acid delivery systems by efficiently targeting cells beyond the liver. As part of the agreement, NanoVation and Novo Nordisk will focus on two lead programs that use base-editing therapies to address rare genetic diseases. The collaboration will also explore up to five additional targets for cardiometabolic and rare diseases. This partnership is a major validation of NanoVation’s platform, as it enables new opportunities for nucleic acid delivery and the development of transformative genetic medicines. According to NanoVation CEO Dominik Witzigmann, PhD, the collaboration is a testament to the potential of their LNP technology in delivering life-changing therapies.
Financial Terms and Strategic Synergies:
Under the terms of the agreement, NanoVation will receive research funding and is eligible for up to $600 million in upfront cash and potential milestone payments. The deal also includes tiered royalties on future product sales. Novo Nordisk will have exclusive worldwide rights to use NanoVation’s lcLNP™ technology for the two lead programs, providing a strong foundation for advancing genetic medicine candidates with curative potential. This partnership aligns the two companies’ strengths—NanoVation’s expertise in nucleic acid delivery and Novo Nordisk’s focus on cardiometabolic and rare disease therapeutics—offering a comprehensive approach to creating innovative, high-impact therapies.
